Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.02 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)3.61M
Market Cap
$1.96B
Enterprise Value$2.57B
Total Cash (Recent Filing)$295.09M
Total Debt (Recent Filing)$794.99M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Jul 31, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding209,250,270
10 Day Avg. Volume3,632,743
30 Day Avg. Volume3,609,600
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)-1.47
Price to Sales (P/S)0.00
P/FCF Ratio-13.08
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit5.27
Enterprise Value/Ebitda-98.54
Forecast
1Y Price Target
$16.45Price Target Upside75.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
BioCryst News
PremiumCompany Announcements
BioCryst Sells European ORLADEYO Business for $264MBulls Say, Bears Say
Bulls Say
Debt And Financial HealthThe sale of the European Orladeyo business allows BCRX to retire a term loan, eliminating approximately $70 million in future interest payments and resulting in significant operational expense savings.
Product Development And Market ExpansionThe FDA's Priority Review and PDUFA target action date for the pediatric formulation of Orladeyo could potentially expand its market by adding an estimated 500 additional patients.
Revenue And Sales GuidanceBCRX has increased its Orladeyo 2025 sales guidance twice this year due to strong market performance and expects significant revenue growth.
Bears Say
Regulatory ChallengesThe extension of the PDUFA target action date for the pediatric formulation of Orladeyo by three months due to a major amendment to the NDA is seen as a minor setback for BCRX.
Regulatory EnvironmentConcerns about recent changes at the FDA and departures of key personnel suggest potential delays for other NDAs under review.
Ownership Overview
1.58% Insiders
17.68% Mutual Funds
31.49% Other Institutional Investors
33.17% Public Companies and Individual Investors
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $6.01 and its highest was $11.31 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.96B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Jul 31, 2025 which is in 31 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on May 05, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.078.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is <0.01.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 209,250,270 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went up 23.516%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
BioCryst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.45 (75.75% Upside)
$16.45 (75.75% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 71%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.19%
12-Months-Change
Fundamentals
Return on Equity
18.68%
Trailing 12-Months
Asset Growth
2.60%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BCRX Company Deck
BCRX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioCryst demonstrated strong financial performance in the first quarter of 2025, with record revenue growth and accelerated profitability. The company successfully reduced its debt and made notable progress in its pipeline, particularly with the pediatric NDA submission for ORLADEYO. While there are challenges in patient recruitment for new programs, the overall sentiment is positive due to the company's financial strength and strategic advancements.Read More>BCRX Stock 12 Month Forecast
Average Price Target
$16.45
▲(75.75%Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
MannKind
―
Agios Pharma
―
Disc Medicine
―
Kymera Therapeutics
―